S-1/A: Profusa Files S-1/A for $100M Equity Line Resale

Profusa, Inc. has filed an amended registration statement to facilitate the resale of up to 179.3 million shares of common stock by selling stockholders.

Summary

• The filing registers the resale of 179,272,293 shares of common stock by selling stockholders, primarily Ascent Partners Fund LLC.
• The registration includes 150,568,827 shares potentially issuable under an Equity Line of Credit (ELOC) facility, which allows the company to raise up to $100 million in gross proceeds.
• Additional shares registered include 20,027,859 shares from convertible notes, 3,333,333 shares from inducement warrants, and 5,342,274 shares from sponsor notes.
• The company is currently in default on certain promissory notes and has received Nasdaq delisting notices, though it is appealing the decision.
• Profusa reported a net loss of $35.8 million for the year ended December 31, 2025, compared to $9.2 million in 2024.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a high-risk filing due to the company's going concern warning, ongoing Nasdaq delisting proceedings, and heavy reliance on dilutive financing mechanisms.

Positives

• Successfully consummated a business combination with NorthView Acquisition Corporation in July 2025.
• Secured an ELOC facility providing potential access to up to $100 million in capital.
• Received approval for the forgiveness of a $1.3 million PPP loan in February 2026.
• Entered into a license agreement with Mayo Clinic for continuous oxygen measurement technology in February 2026.
• Lumee Oxygen platform has received CE Mark approval in the EU.

Negatives

• Substantial doubt exists regarding the company's ability to continue as a going concern.
• Reported a significant increase in net loss to $35.8 million in 2025.
• Currently in default on several promissory notes and convertible notes.
• Subject to Nasdaq delisting proceedings due to failure to meet minimum bid price and market value requirements.
• Identified material weaknesses in internal control over financial reporting.

Risks

• Substantial doubt about the ability to continue as a going concern.
• Potential for significant dilution to existing shareholders from the issuance of shares under the ELOC and conversion of notes.
• Risk of delisting from the Nasdaq Global Market.
• Highly competitive market with well-established rivals in the CGM and oxygen monitoring space.
• Dependence on third-party suppliers and contract manufacturers.
• Uncertainty regarding FDA regulatory approval for Lumee Oxygen and Lumee Glucose in the U.S.

Future Outlook

The company plans to launch Lumee Oxygen in Europe in early 2026 and seek U.S. FDA approval for Lumee Oxygen by late 2026, followed by Lumee Glucose in late 2026 or early 2027. Future operations depend on obtaining additional capital and regulatory clearances.

Management Comments

• Management acknowledges substantial doubt about the company's ability to continue as a going concern.
• Management believes the company's technology platform offers significant advantages over existing market solutions in terms of cost and user experience.

Industry Context

StockSavvy.ai notes that Profusa operates in the highly competitive digital health and medical device sector, where success is heavily dependent on regulatory milestones and capital availability. The company's reliance on an equity line of credit and convertible debt is common for pre-revenue or early-commercial stage biotech firms facing liquidity constraints.

Comparison to Industry Standards

• Competes with established players like Abbott, Medtronic, and Dexcom in the CGM market.
• Faces competition from Siemens Healthineers and Perimed AB in the oxygen monitoring space.
• The company's reliance on external financing and high cash burn is typical for clinical-stage medical device companies.

Corporate Governance

Legal Proceedings

• The company is currently in default on several promissory notes and convertible notes.
• The company is subject to Nasdaq delisting proceedings.

Related Party Transactions

• Convertible notes held by Tasly and NorthView Sponsor I, LLC.
• Promissory notes held by founders.
• Administrative service fee payable to NorthView Sponsor I, LLC.

Stakeholder Impact

• Existing shareholders face significant dilution from the issuance of shares under the ELOC and conversion of notes.
• Potential for delisting could reduce liquidity for shareholders.

Next Steps

• Await Nasdaq Hearings Panel determination regarding continued listing.
• Continue clinical trials for Lumee Glucose.
• Seek FDA marketing authorization for Lumee Oxygen and Lumee Glucose.
• Execute commercialization plans in Europe.

Key Dates

Recommendation

The company faces severe liquidity issues, substantial doubt regarding its going concern status, and potential delisting from Nasdaq. The heavy reliance on dilutive financing and the significant accumulated deficit make this a high-risk investment.

Keywords

Profusa, PFSA, biotech, continuous glucose monitoring, medical devices, equity line of credit, Nasdaq, S-1 filing